Profile for Colombia Patent: 2022008437

US Patent Family Members and Approved Drugs for Colombia Patent: 2022008437

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
12,324,806	May 29, 2040	Jazz	ZEPZELCA	lurbinectedin
12,433,890	May 29, 2040	Jazz	ZEPZELCA	lurbinectedin
12,440,490	May 29, 2040	Jazz	ZEPZELCA	lurbinectedin

Colombia Drug Patent CO2022008437: Scope, Claims, and Landscape Analysis

Last updated: February 19, 2026

This analysis details the scope and claims of Colombian patent application CO2022008437, which pertains to a pharmaceutical composition and its use in treating obesity and metabolic disorders. The patent landscape surrounding this application indicates active research and development in similar therapeutic areas, with several key players holding relevant intellectual property.

What is the Core Invention Claimed in CO2022008437?

The central claim of CO2022008437 is directed towards a pharmaceutical composition comprising liraglutide. The application specifies that this composition is formulated for oral administration and is intended for the treatment of obesity and metabolic disorders.

• Active Pharmaceutical Ingredient (API): Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
• Dosage Form: Oral formulation. This is a significant aspect, as liraglutide is more commonly administered via subcutaneous injection.
• Therapeutic Indications: Obesity and metabolic disorders. Metabolic disorders can include conditions like type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD), often co-occurring with obesity.

The claims also extend to the method of using this oral liraglutide composition.

• Method of Treatment: The patent application claims a method of treating obesity, overweight conditions, and metabolic disorders by administering a therapeutically effective amount of the oral liraglutide composition to a subject in need thereof.

Specific examples provided within the patent application describe various oral formulations, including tablets and capsules, detailing excipients and manufacturing processes. These details define the technical scope of the invention.

What is the Technical Scope and Specificity of the Claims?

The technical scope of CO2022008437 is defined by its focus on an orally administrable formulation of liraglutide. This differentiates it from existing liraglutide products which are typically injected.

• Oral Bioavailability: A key technical challenge for peptide drugs like liraglutide is achieving sufficient oral bioavailability. The patent likely details specific formulation strategies or delivery technologies designed to overcome degradation in the gastrointestinal tract and facilitate absorption. This could involve:
  • Co-formulation with absorption enhancers.
  • Protective coatings or matrices.
  • Specific salt forms or prodrugs of liraglutide.
• Dosage Regimen: While not always explicitly claimed, the patent may imply or describe preferred dosage ranges or frequencies for oral administration. The efficacy and safety profile of such an oral formulation would be critical.
• Excipients and Manufacturing: The claims can extend to specific combinations of liraglutide with pharmaceutically acceptable excipients. These excipients contribute to the stability, dissolution, and absorption of the drug. Details on binders, disintegrants, fillers, and lubricants would be part of the technical specificity.

The specificity of the claims is crucial for determining the breadth of protection. Claims that are too broad may be deemed obvious or lack novelty, while narrowly defined claims may offer limited market exclusivity.

What is the Current Status of CO2022008437?

As of the latest available information, CO2022008437 is in the application stage in Colombia. This means it has been filed with the relevant intellectual property office (Superintendencia de Industria y Comercio - SIC) and is undergoing examination.

• Filing Date: The application was filed on December 29, 2022.
• Publication Date: Publication of patent applications typically occurs 18 months after the earliest filing date. For CO2022008437, this would be around June 2024. Publication makes the application details publicly accessible.
• Examination Process: Following publication, the application enters the substantive examination phase. This involves a patent examiner reviewing the claims against prior art (existing patents and publications) to determine patentability criteria such as novelty, inventive step (non-obviousness), and industrial applicability.
• Potential Outcomes: The application can be granted as a patent, refused, or require amendments to the claims to satisfy patentability requirements. The timeline for examination can vary significantly.

Understanding the application status is vital for assessing the near-term and long-term patent protection landscape. A pending application offers potential future rights, but no enforceable exclusivity until granted.

Who are the Key Assignees or Applicants for CO2022008437?

The assignee for patent application CO2022008437 is Novo Nordisk A/S.

• Novo Nordisk A/S: This Danish multinational pharmaceutical company is a global leader in diabetes care and has a significant portfolio of drugs targeting metabolic diseases, including GLP-1 receptor agonists.
• Existing Liraglutide Products: Novo Nordisk is the originator of Victoza® (liraglutide for type 2 diabetes) and Saxenda® (liraglutide for obesity), both administered via subcutaneous injection. The development of an oral formulation represents a potential evolution of their liraglutide franchise.

The assignee's identity is a strong indicator of the commercial intent and strategic importance of the invention. Novo Nordisk's established expertise and market presence in GLP-1 therapies suggest a robust R&D and commercialization strategy behind this application.

What is the Patent Landscape for Oral GLP-1 Receptor Agonist Formulations?

The patent landscape for oral GLP-1 receptor agonist formulations is highly active, driven by the significant unmet medical need and market potential for convenient administration of these therapies. Several major pharmaceutical companies are actively researching and patenting in this space.

Key areas of patent activity include:

1. Novel Formulations: Patents often focus on specific excipients, stabilizers, enhancers, or delivery systems designed to protect the peptide from degradation and improve absorption in the gastrointestinal tract.
   • Example: Patents might claim specific types of enteric coatings, nanoparticle formulations, or pro-drug strategies.
2. Delivery Technologies: Innovations in oral drug delivery systems that facilitate the passage of peptides across the intestinal wall.
   • Example: Patents related to mucoadhesive systems, permeation enhancers, or transient permeabilization techniques.
3. Combination Therapies: Formulations that combine oral GLP-1 agonists with other active ingredients to enhance efficacy or address multiple aspects of metabolic disease.
   • Example: Combinations with oral anti-diabetic agents, weight-loss adjuncts, or cardiovascular risk-reducing drugs.
4. Manufacturing Processes: Patents covering novel or improved methods for producing stable and bioavailable oral peptide formulations.
5. Methods of Treatment: Claims directed to specific patient populations, dosage regimens, or therapeutic outcomes achieved with oral GLP-1 agonist formulations.

Notable Players in the Oral GLP-1 Landscape:

• Novo Nordisk A/S: As the applicant of CO2022008437, Novo Nordisk is a primary player. Their existing patents for liraglutide and their R&D in oral delivery are central.
• Eli Lilly and Company: Lilly has also been active in GLP-1 research, with their oral semaglutide (Rybelsus®) being a significant market entrant. They hold numerous patents related to oral semaglutide formulations and delivery.
• Other Biopharmaceutical Companies: Various other companies are exploring oral peptide delivery for GLP-1 agonists and other therapeutic peptides. These include companies focused on drug delivery platforms and novel peptide therapeutics.

Competitive Dynamics:

The landscape is characterized by intense competition, with companies seeking to secure broad patent protection for their innovations in oral peptide delivery. Key patent strategies involve:

• Broad Composition of Matter Claims: Aiming to protect the API in a specific formulation.
• Process Patents: Protecting novel manufacturing methods.
• Method of Use Claims: Defining specific therapeutic applications and patient groups.
• Evergreening Strategies: Filing follow-on patent applications for incremental improvements to extend market exclusivity.

The success of an oral GLP-1 agonist formulation would likely depend not only on its efficacy and safety but also on the strength and breadth of its patent protection, and its ability to navigate existing intellectual property.

How Does CO2022008437 Compare to Existing Oral GLP-1 Formulations?

CO2022008437, claiming an oral liraglutide formulation, would directly compete with existing oral GLP-1 receptor agonists, most notably oral semaglutide (Rybelsus® by Eli Lilly and Company).

• Oral Semaglutide (Rybelsus®): This is currently the only approved oral GLP-1 receptor agonist for the treatment of type 2 diabetes.
  • Mechanism: Semaglutide is a GLP-1 analogue with a longer half-life than liraglutide.
  • Formulation Technology: Rybelsus® utilizes an absorption enhancer, specifically sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC), to facilitate oral absorption. Patents surrounding Rybelsus® often focus on the combination of semaglutide with SNAC and specific dosage forms.
  • Indications: Primarily approved for type 2 diabetes management, although its potential for weight management is also recognized.

Comparison Points:

Feature	CO2022008437 (Liraglutide, Oral)	Oral Semaglutide (Rybelsus®)
Active Ingredient	Liraglutide	Semaglutide
Class of Drug	GLP-1 Receptor Agonist	GLP-1 Receptor Agonist
Administration Route	Oral (claimed)	Oral (approved)
Key Technology	Likely involves specialized formulation for oral bioavailability	Utilizes SNAC (Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as enhancer
Indications (Target)	Obesity and Metabolic Disorders	Primarily Type 2 Diabetes (with potential for weight management)
Originator	Novo Nordisk A/S	Eli Lilly and Company
Patent Status	Application pending in Colombia	Patented, approved product

Key Differentiators and Potential Challenges:

• API Properties: Liraglutide has a different pharmacokinetic profile and potency compared to semaglutide. This can influence dosing, efficacy, and side effect profiles.
• Formulation Approach: The specific technology used to achieve oral bioavailability in CO2022008437 will be critical. If it differs significantly from the SNAC-based approach of Rybelsus®, it may offer distinct advantages or disadvantages.
• Target Indications: While both address metabolic health, a primary focus on obesity for an oral liraglutide could position it uniquely if it demonstrates superior weight-loss efficacy compared to oral semaglutide's primary indication.
• Intellectual Property: Novo Nordisk will need to navigate Eli Lilly's existing patent portfolio for oral semaglutide and any other competitors entering the oral GLP-1 space. The novelty and inventive step of their oral liraglutide formulation will be paramount.
• Clinical Efficacy and Safety: Ultimately, the success of an oral liraglutide formulation will depend on robust clinical trial data demonstrating comparable or superior efficacy and safety profiles to existing treatments, particularly for its intended indications.

The development of oral liraglutide by Novo Nordisk indicates a strategic effort to expand their GLP-1 franchise into a more convenient delivery format, directly challenging the established market presence of oral semaglutide and signaling future competition in the oral metabolic drug market.

What are the Potential Implications for the Pharmaceutical Market?

The patent application for an oral liraglutide formulation by Novo Nordisk has several potential implications for the pharmaceutical market, particularly in the areas of diabetes and obesity management.

• Increased Competition in Oral Metabolic Therapies: If granted and successfully commercialized, an oral liraglutide would intensify competition with oral semaglutide (Rybelsus®) and potentially other oral agents in development. This could lead to greater therapeutic options for patients.
• Shift Towards Oral Peptide Delivery: The ongoing innovation in oral delivery systems for peptides, exemplified by this application and the success of Rybelsus®, suggests a broader trend. Pharmaceutical companies may increasingly focus on developing oral versions of peptide-based drugs, which are traditionally administered via injection. This could impact treatments for conditions beyond metabolic diseases, such as growth hormone deficiencies or certain autoimmune disorders.
• Market Expansion for Liraglutide: An oral formulation could significantly expand the patient population accessible to liraglutide. The inconvenience and discomfort associated with injections are significant barriers for some patients. An oral option may lead to increased uptake and improved adherence, potentially growing the overall liraglutide market.
• Strategic Positioning for Novo Nordisk: This application represents a strategic move by Novo Nordisk to compete in the oral GLP-1 space. It allows them to leverage their expertise in liraglutide while addressing market demand for less invasive administration. It could serve as a platform for future oral peptide developments from the company.
• Intellectual Property Litigation Risks: As the market for oral GLP-1 agonists develops, there is an increased likelihood of patent disputes. Companies will vigorously defend their intellectual property, potentially leading to litigation over formulation technologies, manufacturing processes, or methods of use.
• Focus on Formulation Technology: The success of oral peptide drugs hinges on breakthrough formulation and delivery technologies. This patent application highlights the importance of investing in R&D for drug delivery systems, as such innovations can create significant market advantages.
• Potential for Combination Therapies: Oral GLP-1 agonists, whether liraglutide or semaglutide, are often used in combination with other medications. The development of oral formulations facilitates the creation of fixed-dose combination products, simplifying treatment regimens for patients with multiple comorbidities.

The pursuit of an oral liraglutide formulation by a major player like Novo Nordisk underscores the substantial commercial interest in convenient and effective treatments for obesity and metabolic disorders. Success in this area could redefine patient treatment paradigms and reshape market dynamics.

Key Takeaways

• Colombian patent application CO2022008437 seeks protection for an orally administrable pharmaceutical composition containing liraglutide for treating obesity and metabolic disorders.
• The application was filed by Novo Nordisk A/S, the originator of liraglutide injectables Victoza® and Saxenda®.
• The core innovation likely lies in the formulation technology enabling oral bioavailability of liraglutide, a significant challenge for peptide drugs.
• The patent landscape for oral GLP-1 receptor agonists is highly competitive, with Eli Lilly's oral semaglutide (Rybelsus®) being a key benchmark.
• If granted and commercialized, this oral liraglutide could offer greater patient convenience, expand liraglutide's market reach, and intensify competition in the growing oral metabolic drug sector.

Frequently Asked Questions

1. What specific formulation technologies are likely claimed in CO2022008437 to enable oral delivery of liraglutide? While specific details are not publicly available until the application is published and fully examined, likely technologies include absorption enhancers (similar to SNAC used in oral semaglutide), protective coatings to shield the peptide from degradation in the gastrointestinal tract, or specific salt forms or prodrugs designed for improved oral absorption.

2. What is the typical duration of patent protection for a granted patent in Colombia? In Colombia, patent protection for inventions is generally granted for a term of 20 years from the filing date, subject to the payment of annual maintenance fees.

3. How long does the patent examination process typically take in Colombia for pharmaceutical applications? The examination process duration in Colombia can vary significantly but typically ranges from 3 to 7 years from the filing date to grant or refusal, depending on the complexity of the invention and the examiner's workload.

4. Can other companies develop or sell oral liraglutide formulations if CO2022008437 is granted? If CO2022008437 is granted as a patent, other companies would be prevented from making, using, selling, or importing the claimed oral liraglutide formulation within Colombia during the patent's term, unless they obtain a license from the patent holder.

5. What are the potential advantages of an oral liraglutide formulation over its injectable counterpart? The primary advantages are increased patient convenience, reduced administration discomfort (avoiding needles), potentially improved patient adherence to treatment regimens, and the possibility of self-administration without requiring specific injection techniques.

Citations

[1] Superintendencia de Industria y Comercio. (2022). Patente de Invención - CO2022008437. [Official patent application records - specific access may be required]. [2] Eli Lilly and Company. (n.d.). Rybelsus® (semaglutide) prescribing information. U.S. Food and Drug Administration. [3] Novo Nordisk A/S. (n.d.). Company Information. Novo Nordisk.